BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29802458)

  • 1. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.
    Danilov AV; Li H; Press OW; Shapira I; Swinnen LJ; Noy A; Reid E; Smith SM; Friedberg JW
    Leuk Lymphoma; 2017 Feb; 58(2):461-465. PubMed ID: 27386786
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
    Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].
    Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T
    Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current Standards in the Treatment of Hodgkin Lymphoma].
    Hellmuth JC
    Dtsch Med Wochenschr; 2024 Jun; 149(12):702-708. PubMed ID: 38781993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin lymphoma: A review and update on recent progress.
    Shanbhag S; Ambinder RF
    CA Cancer J Clin; 2018 Mar; 68(2):116-132. PubMed ID: 29194581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
    Burton C; Allen P; Herrera AF
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin lymphoma treatment for older persons in the modern era.
    Evens AM; McKenna M; Ryu Tiger YK; Upshaw JN
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):483-499. PubMed ID: 38066840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin lymphoma: Focus on evolving treatment paradigms.
    Roswarski JL; Longo DL
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycosis fungoides: successful re-treatment with brentuximab vedotin.
    James M; Nakamura M; Whittaker S; Morris S
    Br J Dermatol; 2024 May; 190(6):929-930. PubMed ID: 38470968
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of limited-stage Hodgkin lymphoma.
    Al-Juhaishi T; Ahmed S
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):500-509. PubMed ID: 38066938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a cure for cHL without chemotherapy.
    Lynch RC
    Blood; 2024 Feb; 143(9):741-742. PubMed ID: 38421817
    [No Abstract]   [Full Text] [Related]  

  • 15. New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
    Diefenbach C; Steidl C
    Clin Cancer Res; 2013 Jun; 19(11):2797-803. PubMed ID: 23447000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients-role of maintenance therapy in the real world.
    Damlaj M; Tlayjeh M; Damlaj A; Alahmari B; AlSadi H; Ahmed M; AlJubour Z; Alhejazi A; Salama H; Ibrahim A; Al Raizah A; Bakkar M; Ghori A; Al Saleh AS; Alaskar A; Alzahrani M
    Bone Marrow Transplant; 2023 Oct; 58(10):1160-1162. PubMed ID: 37464089
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody based therapies in Hodgkin lymphoma.
    Radhakrishnan VS; Longley J; Johnson PWM
    Cancer Treat Rev; 2024 Jan; 122():102647. PubMed ID: 37988820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
    Moskowitz CH; Walewski J; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Viviani S; Bachanova V; Sureda A; McClendon T; Lee C; Lisano J; Sweetenham J
    Blood; 2018 Dec; 132(25):2639-2642. PubMed ID: 30266774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?
    Chen RW
    Ann Transl Med; 2018 Jun; 6(11):238. PubMed ID: 30023401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.